Safety and efficacy of HFA-134a beclomethasone dipropionate extra-fine aerosol over six months

Canadian Respiratory Journal

Volumn 11, Issue 2, 2004, Pages 123-130

  Boulet, Louis Philippe ^a   Cartier, André ^b   Ernst, Pierre ^c   Larivée, Pierre ^d   Laviolette, Michel ^a  

^a LAVAL UNIVERSITY   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Asthma; Hydrofluoroalkane beclomethasome dipropionate; Inhaled corticosteroids; Systemic safety

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CORTICOTROPIN; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; HYDROCORTISONE; LORAZEPAM; NEDOCROMIL; NORFLURANE; SHORT ACTING DRUG; THEOPHYLLINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AEROSOL; ARTICLE; ASTHMA; BACKACHE; BRONCHITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPEPSIA; DYSPHONIA; ENDOCRINE DISEASE; FEMALE; FREQUENCY ANALYSIS; HEADACHE; HEART PALPITATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRAOCULAR PRESSURE ABNORMALITY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINUSITIS; SKIN BRUISING; TACHYCARDIA; THORAX PAIN; THRUSH; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS; VIRUS INFECTION;

EID: 1942475183     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/823084     Document Type: Article

References (23)

1. Boulet LP, Cockcroft DW, Toogood J, Lacasse Y, Baskerville J, Hargreave FE. Comparative assessment of safety and efficacy of inhaled corticosteroids: Report of a committee of the Canadian Thoracic Society. Eur Respir J 1998;11:1194-210.
2. Boulet LP, Becker A, Berube D, Beveridge R, Ernst P. Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. CMAJ 1999;161(11 Suppl):S1-61.
3. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-ftee HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998;12:1346-53.
4. Gabrio BJ, Stein SW, Velasquez DJ. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int J Pharm 1999;186:3-12.
5. Conway JH, Walker P, Perkins G, et al. Lung deposition characteristics of HFA-134a beclomethasone dipropionate delivered via an Autohaler™. Eur Respir J 1999;14(Suppl 30):196S, P1360.
6. Busse WW, Brazinsky S, Jacobsen K, et al. Efficacy response on inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999;104:1215-22.
7. Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma. Chest 1999;115:343-51.
8. Davies RJ, Stampone P, O'Connor BJ. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the daily dose. Respir Med 1998;92(Suppl A):23-31.
9. Magnussen H. Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Respir Med 2000;94:549-55.
10. Fireman P, Prenner BM, Vincken W, Demedts M, Mol SJ, Cohen RM. Long-term safety and efficacy of a CFC-free beclomethasone dipropionate extrafine aerosol. Ann Allergy Asthma Immunol 2001;86:557-65.
11. Harrison LI, Soria I, Cline AC, Ekholm BP. Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. J Pharm Pharmacol 1999;51:263-9.
12. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects (Version current at March 3, 2004).
13. Juniper E, Cockcroft DW, Hargreave FE. Histamine and methacholine inhalation tests: Tidal breathing method. Laboratory procedure and standardization. Canadian Thoracic Society. Lund: AB Draco, 1991.
14. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-36.
15. Busse WW, Banks-Schlegel S, Wenzel SE. Pathophysiology of severe asthma. J Allergy Clin Immunol 2000;106:1033-42.
16. Boulet LP, Markers of systemic actions of corticosteroids. In: Schleimer RP, O'Byrne PM, Szefler SJ, Brattsand R, eds. Inhaled Steroids in Asthma: Optimizing Effects in the Airways. New York: Marcel Dekker, 2002:465-90.
17. Vanden Burgt JA, Busse WW, Martin RJ, Szefler SJ, Donnell D. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol. 2000;106:1209-26.
18. Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996;154:1505-10.
19. Kraft M. The distal airways: Are they important in asthma? Eur Respir J 1999;14:1403-17.
20. Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997;100:44-51.
21. Evans DJ, Green M. Small airways: A time to revisit? Thorax 1998;53:629-30.
22. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-64.
23. Polgar G, Promadaht V. Pulmonary Function Testing in Children: Techniques and Standards. Philadelphia: WB Saunders, 1971:272.